In the Journals

No adverse events reported for patients with egg allergy receiving live attenuated influenza vaccine

Patients with an egg allergy did not experience systemic allergic reactions when administered live attenuated influenza vaccine — which contains egg protein — according to a recent study.

“We have previously reported that [live attenuated influenza vaccine] LAIV is unlikely to contain enough egg protein to trigger an [immunoglobulin E (IgE)] mediated allergic reaction in people with egg allergy,” Paul J. Turner, FRACP, PhD, from the section of paediatrics, Imperial College London in London, U.K., and colleagues wrote. “The risk of causing a systemic allergic reaction with quadrivalent LAIV therefore seems to be no greater in young people with egg allergy (including those with a history of anaphylaxis to egg) compared with those without egg allergy.”

Turner and colleagues evaluated 779 patients from 30 allergy centers in the United Kingdom who received LAIV. Of these patients, 34.7% (n = 270) had previously shown an anaphylactic reaction to egg, with 20.1% of patients (n = 157) having cardiovascular or respiratory symptoms, according to the abstract. Overall, 57.1% of patients in the group had asthma or recurrent wheeze symptoms.

Researchers administered LAIV that contain more than 0.3 ng/mL ovalbumin to 667 patients, and 511 patients received a vaccine that contained between 1 ng/mL and 1.93 ng/mL of ovalbumin. After administering LAIV, Turner and colleagues monitored the patients for 30 minutes and contacted the patients again at 72-hour follow-up. Patients who had asthma or recurrent wheeze symptoms received another follow up at 4 weeks after vaccination.

The researchers found no patients in their study had a systemic adverse reaction to the vaccination. However, 17 patients did experience complications in the study that appeared within 2 hours of vaccination. Two patients reported skin symptoms between 30 minutes and 120 minutes of vaccination who later had no adverse reactions when tested with a second LAIV immunization 4 weeks later. The 95% upper CI for the general population was 0.47% and 1.36% for patients with an egg allergy, according to the abstract.

In 221 patients, some adverse events were reported within 72 hours of LAIV administration that could potentially be related to the vaccine. Specifically, 62 patients had lower respiratory tract symptoms within 72 hours (8.1%; 95% CI, 6.3-10.3) and 29 patients had wheeze symptoms, according to the abstract. However, Turner and colleagues reported no lower respiratory tract reactions in the 4 weeks following the vaccination. – by Jeff Craven

Disclosure: The researchers report no relevant financial disclosures.

Patients with an egg allergy did not experience systemic allergic reactions when administered live attenuated influenza vaccine — which contains egg protein — according to a recent study.

“We have previously reported that [live attenuated influenza vaccine] LAIV is unlikely to contain enough egg protein to trigger an [immunoglobulin E (IgE)] mediated allergic reaction in people with egg allergy,” Paul J. Turner, FRACP, PhD, from the section of paediatrics, Imperial College London in London, U.K., and colleagues wrote. “The risk of causing a systemic allergic reaction with quadrivalent LAIV therefore seems to be no greater in young people with egg allergy (including those with a history of anaphylaxis to egg) compared with those without egg allergy.”

Turner and colleagues evaluated 779 patients from 30 allergy centers in the United Kingdom who received LAIV. Of these patients, 34.7% (n = 270) had previously shown an anaphylactic reaction to egg, with 20.1% of patients (n = 157) having cardiovascular or respiratory symptoms, according to the abstract. Overall, 57.1% of patients in the group had asthma or recurrent wheeze symptoms.

Researchers administered LAIV that contain more than 0.3 ng/mL ovalbumin to 667 patients, and 511 patients received a vaccine that contained between 1 ng/mL and 1.93 ng/mL of ovalbumin. After administering LAIV, Turner and colleagues monitored the patients for 30 minutes and contacted the patients again at 72-hour follow-up. Patients who had asthma or recurrent wheeze symptoms received another follow up at 4 weeks after vaccination.

The researchers found no patients in their study had a systemic adverse reaction to the vaccination. However, 17 patients did experience complications in the study that appeared within 2 hours of vaccination. Two patients reported skin symptoms between 30 minutes and 120 minutes of vaccination who later had no adverse reactions when tested with a second LAIV immunization 4 weeks later. The 95% upper CI for the general population was 0.47% and 1.36% for patients with an egg allergy, according to the abstract.

In 221 patients, some adverse events were reported within 72 hours of LAIV administration that could potentially be related to the vaccine. Specifically, 62 patients had lower respiratory tract symptoms within 72 hours (8.1%; 95% CI, 6.3-10.3) and 29 patients had wheeze symptoms, according to the abstract. However, Turner and colleagues reported no lower respiratory tract reactions in the 4 weeks following the vaccination. – by Jeff Craven

Disclosure: The researchers report no relevant financial disclosures.